Viral gene delivery is adept at the persistent expression of therapeutic transgenes, e.g., for gene replacement therapies against rare diseases, or long-lived CAR-T cells. In contrast, nonviral genetic medicines can provide transient efficacy against conditions where doses must be safely repeated or “dialed-in.” As of this writing, there’s mass-produced mRNA for two SARS-CoV-2 vaccines and additionally, four siRNA drugs approved by regulatory authorities. Yet today—while not an impossible challenge—efficient and non-cytotoxic delivery of nucleic acids sans viruses still remains a “grand problem.” This is especially true for many primary cell types that lack a transformed phenotype. Can this perennial pain point be remedied for ex vivo cell engineering of regenmed therapies?
Learn how the RoosterGEM™ complete genetic engineering medium can help navigate the pitfalls with mRNA transfection and assist in lentivirus-mediated transduction of human mesenchymal stromal/stem cells (hMSCs).